The FDA has already approved three CDK4/6 inhibitors for lifelong breast cancer therapy (palbociclib, abemaciclib, ribociclib), which mainly work by avoiding the G1 to S cell-cycle phase transition. This evidence concerns the gene CDK4 and breast carcinoma.